A Comparison of Death Domain-Associated Protein 6 in Different Endometrial Carcinomas Histotypes

Cao Jin1, Sean Hacking1, Miglena K Komforti2 and Mansoor Nasim1

1Department of Pathology, Northwell Health Systems, New Hyde Park, NY, USA.
2Department of Pathology, Montefiore Medical Center, Bronx, NY, USA.

ABSTRACT

BACKGROUND: Death domain-associated protein 6 (DAXX) is involved in regulating apoptosis via subcellular localization. The presence of DAXX point mutations correlates well with loss of nuclear expression on immunohistochemistry (IHC). In this study, we sought to determine (1) whether DAXX expression pattern is the same across different uterine carcinoma subtypes, and (2) which uterine carcinomas show loss of nuclear DAXX IHC.

DESIGN: We studied 65 uterine carcinomas of the following histologic types: 30 endometrioid (12 FIGO grade 1, 12 FIGO grade 2, and 6 FIGO grade 3), 8 serous, 14 clear cell, and 13 undifferentiated/dedifferentiated type (UEC/DDEC). Nuclear DAXX IHC was assessed in each tumor and was graded semi-quantitatively as follows: 0% to 50%, 50% to 75%, and greater than 75% of lesional cells react.

RESULTS: A total of 61% (25/41) of high-grade carcinomas (FIGO grade 3, serous, clear cell, and UEC/DDEC) showed retained DAXX nuclear staining in >75% of lesional cells, compared with only 4.2% (1/24) of the low-grade carcinomas (FIGO grades 1 and 2) (P = .0001), where DAXX expression was cytoplasmic. In addition, in the 11 DDEC cases, all the differentiated components showed loss of nuclear DAXX compared with the undifferentiated components which retained nuclear DAXX expression.

CONCLUSIONS: We demonstrate that loss of nuclear DAXX is present in low-grade endometrial carcinomas and the differentiated components in UEC/DDEC, but not in high-grade ones, suggesting DAXX’s role in tumor progression and its potential as a therapeutic target in high-grade endometrial carcinomas.

KEYWORDS: Endometrial carcinoma, uterine carcinoma, DAXX, histone chaperone

Received: June 28, 2019. Accepted: June 28, 2019.

Type: Original Research

Funding: The author(s) received no financial support for the research, authorship, and/or publication of this article.

Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Corresponding Author: Mansoor Nasim, Department of Pathology, Northwell Health Systems, 6 Ohio Drive, Suite 202, Lake Success, New Hyde Park, NY 11042, USA. Email: Mnasim@northwell.edu

Introduction

Uterine endometrial carcinomas (UECs) are the most common gynecologic neoplasms in the United States. They represent a histologically diverse group of tumors with different pathological features. High-grade endometrial cancers include serous, clear cell, and undifferentiated/dedifferentiated carcinomas (UEC/DDEC), the latter being more likely to recur/metastasize while carrying the worst prognosis. Currently, despite increased understanding regarding the molecular pathways involved in the pathogenesis of UEC, the prognosis for advanced disease is still poor, with options for targeted therapies still lacking. An expansion of prognostic and therapeutic markers in UECs is urgently needed: to reflect the complexity of the carcinomas, to provide a more accurate stratification, and to allow for more effective therapies.

Death domain-associated protein-6 (DAXX), a predominantly nuclear protein, was originally death receptor binding protein. It has been shown to be important for enhancing Fas-mediated apoptosis through its interaction with JNK (c-Jun N-terminal kinase). The physiological function of DAXX relies on its ability to shuttle between the nucleus and the cytoplasm. It has been reported that in neurons, the function of DAXX varies according to its localization: for example, when DAXX is located in the nucleus, it is anti-apoptotic, whereas when it is localized in the cytoplasm, it is pro-apoptotic. Per contra, an example of the former is that of diffuse large B-cell lymphoma, where DAXX is considered a cancer-promoting (while retained in the nucleus). Therefore, patients who have high nuclear DAXX expression, in some tumors, tend to have a worse prognosis.

In addition to this, numerous studies have shown that DAXX mutations are present in various types of tumors, such as oral cancers, pancreatic neuroendocrine tumors, urothelial carcinomas, prostate cancers, glioblastomas, ovarian cancers, and so on. While per contra to previously suggested, other studies have shown that loss of DAXX (nuclear) correlates with worse clinical behaviors. Furthermore, given the important regulatory role of DAXX in apoptosis, multiple preliminary studies have shown promising therapeutic value in DAXX-targeted cancer treatment (in vivo studies). Despite this, there have been no studies examining the role of DAXX in endometrial carcinomas.

In view of these considerations, the aim of this study was to examine the subcellular localization of DAXX in tissue samples...
Materials and Methods

Case selection and classification

A total of 65 uterine carcinomas were identified in our institutional pathology database from 2010 to 2017. A subset of 30 endometrioid type (12 FIGO grade 1, 12 grade 2, and 6 grade 3), 8 serous type, 14 clear cell type (CCC), and 13 undifferentiated/dedifferentiated type (UEC/DDEC) were reviewed independently by 2 senior gynecological pathologists to confirm the diagnosis and to identify the best tumor-containing slide. Another random selection of 13 benign endometrium biopsies were also included in the study for comparison. The endometrium specimens included 5 cases of secretory endometrium and 8 cases of proliferative endometrium. Patient ages at resection ranged from 39 years to 90 years old, with all specimens being hysterectomies. The tissues were prepared in paraffin-embedded blocks for pathological diagnosis.

Immunohistochemical analysis

Immunohistochemical stains for DAXX (Anti-DAXX [Sigma Life Science; HPA008736, 1:100]) were assessed on tissue sections. The staining protocol and controls are submitted in Supplemental material.

Loss of DAXX expression was semi-quantified as <50% nuclear labeling within the tumor cells, 50% to 75% (dominant pattern) and more than 75% (significant pattern). Tumors with absent DAXX expression were required to have positive internal controls (normal endothelial, stromal, or inflammatory cells) before being considered negative. All the staining was performed at the Immunopathology Laboratory of Long Island Jewish Medical Center (Northwell Health System, New Hyde Park, NY).

Statistics

Statistical analysis was performed using the 2-tailed Fisher exact test and Student t tests (vassarstats.net) depending on the type of variables being analyzed. This work was approved by the Institutional Review Board of Northwell Health Systems.

Results

DAXX staining was performed on a total of 65 cases: a subset of 30 endometrioid type (12 grade 1, 12 grade 2, and 6 grade 3), 8 serous type, 14 clear cell type, and 13 UEC/DDEC together with an additional 13 benign endometrium (5 secretory phase and 8 proliferative phase) for comparison (Table 1). The mean ages for endometrial carcinoma patients were 63.4 ± 13.4 (range = 55–90) years, while the ages for benign endometrium were 45.2 ± 2.5 (range = 39–48) years (P < .05).

All of the cases showed both nuclear and cytoplasmic staining. The percentage of nuclear staining was quantified in each case. A variable spectrum of nuclear DAXX expression was identified among different tumor histotypes (Figure 1).

Among the endometrial carcinoma cases, 2/65 (3.1%) were FIGO stage IV, 8/65 (12.3%) were FIGO stage III, 11/65
(16.9%) were FIGO stage II, and 44/65 (67.7%) were FIGO stage I. When using the cut-off value of 50%, the dominant (50%-75%) and significant pattern (>75%) nuclear DAXX expression were observed in 9/14 (64.3%) CCC, 6/8 (75%) serous carcinoma, and 6/6 (100%) FIGO grade 3 endometrioid carcinoma. In contrast, only 2/12 (16.7%) FIGO grade 1 and 1/12 (8.3%) FIGO grade 2 endometrioid carcinomas showed a (dominant or significant) nuclear staining pattern. Nuclear DAXX expression was found to be significantly higher in high-grade endometrial carcinomas (34/41) than in low-grade endometrial carcinomas (3/24) (82.9% vs 12.5%, $P < .0001$) (Table 2).

Especially, in the 11 DDEC cases, all the differentiated components (low grade) showed less DAXX staining (nuclear) retention compared with the undifferentiated components, where DAXX was mainly retained (Figure 2).

The normal endometrium interestingly showed different staining patterns (between secretory and proliferative types) (Figure 3). By using the cut-off of 50%, the proliferative endometrium had 6/8 (75%) cases show a dominant nuclear staining pattern; this was higher when compared with secretory endometrium (2/5, 40%). Ultimately, there was no statistically significant difference between the groups ($P = .29$). However, when a cut-off of 75% was used, significant nuclear DAXX
staining was more frequently seen in proliferative endometrium when compared with secretory endometrium \((P = .021)\). The secretory endometrium tended to have lower nuclear DAXX than in high-grade cancers \((P = .06)\), although there was no difference between high-grade cancers and proliferative endometrium \((P = .63)\). In contrast, proliferative endometrium
showed higher nuclear DAXX than low-grade carcinoma groups ($P=0.0021$), although there was no difference between low-grade carcinoma groups and secretory endometrium ($P=0.19$). The results are summarized in Table 2.

**Discussion**

In our current study, DAXX analysis yielded variable patterns among the different endometrial histotypes. High-grade endometrial carcinomas tended to have higher percentage of nuclear staining (in tumor cells) than low-grade types. The normal endometrium also presented with different staining patterns, with more nuclear staining being seen in proliferative endometrium than secretory endometrium. Although expression of DAXX has been studied in a variety of tumors, no such studies have been performed in endometrial carcinomas.

DAXX was originally identified as pro-apoptotic factor, with its role in apoptosis being controversial and possibly related to its subcellular localization. It has long been known that protein and its subcellular localization can be closely related to tumor progression. For example, S100A4 is a prognostic variable in breast cancer, which varies depending on its subcellular localization. Similarly and as previously mentioned, while in neurons, the function of DAXX varies also according to its localization: when DAXX is located in the nucleus, it is anti-apoptotic, whereas when it is localized in the cytoplasm, it is pro-apoptotic. In addition, recent findings in gastric cancers showed that an increased DAXX (nuclear/cytoplasmic ratio) was significantly higher in cancer tissues than in adjacent normal tissues. The possible anti-apoptotic role of DAXX is also implied in our observational study, which suggests that nuclear DAXX is higher in normal proliferative endometrium (possibly being anti-apoptotic) than in secretory endometrium (possibly being pro-apoptotic), while nuclear DAXX expression also showed higher expression in high-grade endometrial carcinomas than in low-grade carcinomas (using 2 different cut-off points). More convincingly, in dedifferentiated cases, almost all the tumors cells retained nuclear staining, while the adjacent differentiated components showed less nuclear staining.

Worth mentioning is that the nuclear expression of DAXX was not significantly different when comparing high-grade endometrial carcinomas and proliferative endometrium. This finding is not surprising as endometrial carcinomas are usually seen in the background of proliferative endometrium. However, ultimately, in the progression to high-grade endometrial carcinomas, other proteins are also necessary (in addition to DAXX).

Interestingly, most of the low-grade endometrial carcinomas showed much less nuclear DAXX expression. Recently, with the advent toward molecular classification of endometrial carcinomas, genomic information has been gradually integrated into traditional histological classification systems. It has been shown that endometrioid type carcinomas actually represent a heterogeneous group of carcinomas with different molecular signatures, such as copy-number low variant, POLE (DNA Polymerase Epsilon, Catalytic Subunit) gene hotspot mutated, and MSI-H (microsatellite instability-high), while the high-grade endometrial carcinomas tend to be high copy-number variant. Therefore, low nuclear DAXX expression, in either low- or high-grade groups, may follow a different molecular pathway than those of high nuclear DAXX expression.

Whether loss of nuclear staining is due to DAXX mutations or protein relocation currently remains unknown. Studies have shown that loss of nuclear DAXX on IHC may be a surrogate marker for the presence of DAXX mutations, which may partly explain its pathogenesis in low-grade endometrial carcinomas. Conversely, in high-grade endometrial carcinomas, retained nuclear DAXX may stem from reduced nuclear- to cytoplasm protein relocation, which establishes one of the crucial hallmarks of carcinogenesis (self-initiated continuous tumor proliferation). We did not perform molecular analysis, which is a limitation in our current study. Therefore, whether loss of nuclear staining is due to DAXX mutations, protein relocation, or something else remains to be further elucidated. Finally, regarding the DAXX staining pattern of the uninvolved biopsy-retrieved endometrium, in our study, strong nuclear staining was seen in the proliferative but not in secretory endometrium. This is possibly due to the anti-apoptotic/proliferative role of DAXX. Ultimately, however, only further research will allow us to fully understand its complete role.

Another newly established function of DAXX is its regulation of telomeres. Telomere elongation and maintenance is likely partially responsible for cancer progression. There are 2 main telomere maintenance mechanisms that have been described: telomerase dependent and telomerase independent (such as alternative lengthening of telomeres [ALT]). A common mechanism of carcinogenesis in telomerase-dependent pathway is mutations in the promoter of the telomerase reverse transcriptase ($TERT$) gene. Whereas in the telomerase independent pathway, an ALT (alternative lengthening of telomeres) phenotype, which uses homologous recombination for telomere length maintenance (instead of activation of the telomerase enzyme), is ultimately implicated in the progression of multiple cancer types (especially in brain tumors and sarcomas).

DAXX also interacts with ATRX (alpha-thalassemia/mental retardation syndrome X-linked) to form a protein complex, which can function as an H3.3-specific histone chaperone, while incorporating H3.3 into telomeres, thus contributing to the regulation of ALT. It has been reported that 80% of tumors with an ALT phenotype have mutations in either ATRX or DAXX. Loss of ATRX and/or DAXX has been associated with an ALT phenotype in multiple tumor types, such as sarcomas, pancreatic neuroendocrine tumors, gliomas, and uterine leiomyosarcomas. However, only up to 3% of
endometrial carcinomas harbor an ALT phenotype. Therefore, the common loss of DAXX in low-grade endometrial carcinomas might not explain its role in contributing to the regulation of ALT.

Finally, endometrial carcinoma represents a heterogeneity of different histotypes. Each type may carry different histopathological features and genetic signatures. In our study, the heterogeneous DAXX expression pattern found in its different histotypes may suggest a potential role for target therapy. In vitro studies have already established its therapeutic value, as inhibiting DAXX was found to arrest the growth of glioblastoma in mice models. In the therapeutic context, several approaches to target DAXX have been investigated, including using peptides or small molecules to disrupt DAXX interaction with chromatin-associated proteins.

Our study is not without limitations. The major concern is that we were not able to validate the specificity of the antibody by Western blot. Although we had positive and negative controls (IHC) for DAXX, ideally, a reaction with DAXX-rich and DAXX-deficient tissue on blots can give more convincing results. Second, we did not have precursor lesions in our study, including atypical endometrial hyperplasia with atypia. Including such cases would give us a clearer spectrum of DAXX expression in the pathogenesis of endometrial carcinomas.

In summary, we conclude that loss of DAXX protein expression is associated with low-grade endometrial carcinomas. With DAXX expression being found to be significantly higher in high-grade endometrial carcinomas, it is possible that future cancer therapies could target this pathway, which may have significant implications for treating patients with endometrial carcinomas.

Authors’ Note
This study was presented at USCAP 2019 National Harbor as poster. It has never been published elsewhere.

Acknowledgements
The authors thank Claudine Alexis and Kathy Quinn for their role as researchers and coordinators.

Author contributions
CJ and MN developed the theoretical formalism, performed the analytic calculations and performed the numerical simulations. Both CJ and SH contributed to the final version of the manuscript. MK contributed to the collection of the cases.

ORCID iDs
Cao Jin https://orcid.org/0000-0001-6275-8069
Mansoor Nasim https://orcid.org/0000-0002-6395-0842

Patients’ Consent Waiver Statement
This is a retrospective study which involved only de-identified information. The consent is not required as per Northwell Health Institutional Review Board (IRB) board. The IRB number for this study is 18-0890.

Supplemental Material
Supplemental material for this article is available online.

REFERENCES
1. Kurman RJ, Carcangiu ML, Herrington CS, Young RH. World Health Organization Classification of Tumors of Female Reproductive Organs. Lyon, UK: IARC Press; 2014.
2. Murali R, Delair DF, Bean SM, Abu-Rustum NR, Soslow RA. Evolving roles of histologic evaluation and molecular/genomic profiling in the management of endometrial cancer. J Natl Compr Canc Netw. 2018;16:201–209.
3. Talhouk A, McConathy MK, Leung S, et al. A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer. 2015;113:299–310.
4. Tang X, Khoosavi-Far R, Chang HY, Baltimore D. DAXX, a novel Fas-binding protein that activates JNK and apoptosis. Cell. 1997;89:1067–1076.
5. Dyer MA, Qadeer ZA, Valle-Garcia D, Bernstein E. ATRX and DAXX: mechanisms and mutations. Cold Spring Harb Perspect Med. 2017;7:a026567.
6. Pluta AF, Earnshaw WC, Goldberg IG. Interphase-specific association of intrinsic centromere protein CENP-C with HDAXX, a death domain-binding protein implicated in Fanconi-mediated cell death. J Cell Sci. 1998;111:2029–2041.
7. Dionne KR, Zhuang Y, Leser JS, Tyler KL, Clarke P. DAXX upregulation within the cytoplasm of reovirus-infected cells is mediated by interferon and contributes to apoptosis. J Virol. 2013;87:3447–3460.
8. Horvitz E, Sharratt T, Hill K, et al. A role for eukaryotic initiation factor 4B overexpression in the pathogenesis of diffuse large B-cell lymphoma. Leukemia. 2014;28:1092–1102.
9. Pan WW, Zhou JJ, Liu XM, et al. Death domain-associated protein DAXX promotes ovarian cancer development and chemoresistance. J Biol Chem. 2013;288:13620–13630.
10. Zizzi A, Montironi MA, Mazzucchelli R, et al. Immunohistochemical analysis of chromatin remodeler DAXX in high grade urothelial carcinoma. Diagn Pathol. 2013;8:111.
11. Puto LA, Breougard J, Hunter T. Transcriptional repressor DAXX promotes prostate cancer tumorigenicity via suppression of autophagy. J Biol Chem. 2015;290:15406–15420.
12. Lin GJ, Huang YS, Lin CK, et al. DAXX and TCF4 interaction links to oral squamous cell carcinoma growth by promoting cell cycle progression via induction of cyclin D1 expression. Clin Oral Investig. 2016;20:533–540.
13. Schwartzentruber J, Korshunov A, Liu XY, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature. 2012;482:226–231.
14. Lorich DJ, Kurrer AS, Vasselle E, et al. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors. Gastroenterology. 2014;146:453.e5–460.e5.
15. Zlobin A, Wyatt D, Bloodworth JC, et al. DAXX is a novel notch-1 gene target and biomarker of GSI-sensitivity in ER+ breast cancer. Cancer Res. 2016;76:LB-121.
16. Lin CW, Wang LK, Wang SP, et al. DAXX inhibits hypoxia-induced lung cancer cell metastasis by suppressing the HIF-1α/HDAC1/Slug axis. Nat Commun. 2016;7:13867.
17. Garcia HH, Bray GA, Nguyen DH, Bjeldanes LF, Firestone GL. Indole-3-Carbinol (13C) inhibits cyclin-dependent kinase-2 function in human breast cancer cells by regulating the size distribution, associated cyclin E forms, and subcellular localization of the CDK2 protein complex. J Biol Chem. 2005;280:8756–8764.
18. Lobo GP, Waite KA, Planchon SM, Romigh T, Nassif NT, Eng C. Germ line and somatic cancer-associated mutations in the ATP-binding motif of PTEN influence its subcellular localization and tumor suppressive function. Hum Mol Genet. 2009;18:2851–2862.
19. Egeland EV, Boye K, Park D, Synnestvedt M, Sauer T. Prognostic significance of S100A4-expression and subcellular localization in early-stage breast cancer. Breast Cancer Res Treat. 2017;162:127–137.
20. Xu JF, Zhao ZG, Ye LL, et al. Prognostic significance of DAXX NCR (Nuclear/Cytoplasmic Ratio) in gastric cancer. Cancer Med. 2017;6:2063–2075.
21. Salomoni P, Khelifi AF. DAXX: death or survival protein? Trends Cell Biol. 2006;16:97–104.
22. Dilley RL, Greenberg RA. Alternative telomere maintenance and cancer. Trends Cancer. 2015;1:145–156.
23. De Vitis M, Berardinelli F, Sgura A. Telomere length maintenance in cancer: at the crossroad between telomerase and alternative lengthening of telomeres (ALT). *Int J Mol Sci*. 2018;19:606.

24. Heaphy CM, Subhawong AP, Hong SM, et al. Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. *Am J Pathol*. 2011;179:1608–1615.

25. Heaphy CM, de Wilde RF, Jiao Y, et al. Altered telomeres in tumors with ATRX and DAXX mutations. *Science*. 2011;333:425.

26. Panse G, Chrisinger JS, Leung CH, et al. Clinicopathological analysis of ATRX, DAXX and NOTCH receptor expression in angiosarcomas. *Histopathology*. 2018;72:239–247.

27. Ahvenainen TV, Makinen NM, von Nandelstadh P, et al. Loss of ATRX/DAXX expression and alternative lengthening of telomeres in uterine leiomyomas. *Cancer*. 2018;124:4650–4656.

28. Slatter TL, Hsia H, Samaranayaka A, et al. Loss of ATRX and DAXX expression identifies poor prognosis for smooth muscle tumours of uncertain malignant potential and early stage uterine leiomyosarcoma. *J Pathol Clin Res*. 2015;1:95–105.

29. Haase S, Garcia-Tahiani MB, Carney S, et al. Mutant ATRX: uncovering a new therapeutic target for glioma. *Expert Opin Ther Targets*. 2018;22:599–613.

30. Boohaker RJ, Lee MW, Vishnubhotla P, Perez JM, Khaled AR. The use of therapeutic peptides to target and to kill cancer cells. *Curr Med Chem*. 2012;19:3794–3804.